(AIM: SAR)

23 May 2011

SAREUM HOLDINGS PLC
(“Sareum” or the “Company”)

 

Sareum Website Update

Sareum (AIM: SAR), the specialist cancer drug discovery business, is pleased to announce that the following documents are now available for download at the Company’s website, www.sareum.co.uk:

  • Sareum Research Note dated 23 May 2011, prepared by the Company’s broker, Hybridan LLP
  • Presentation given by Dr John Reader at the One Nucleus Oncology Leadership Meeting, 12 May 20

Sareum Holdings plc

 

Tim Mitchell

01223 497 700

Merchant Securities Limited (Nomad)

Simon Clements

020 7628 2200

Hybridan LLP (Broker)

 

Claire Noyce

020 7947 4350

Notes for editors:

About Sareum Holdings plc

Sareum is a drug discovery company, headquartered in Cambridge UK, that is focused on producing targeted small molecule therapeutics to address unmet medical needs, primarily in cancer. Sareum aims to successfully deliver drug candidates for licensing to pharmaceutical and biotechnology companies at the pre-clinical or early clinical trials stage.

Sareum’s Chk1 kinase cancer research programme is a joint research collaboration with The Institute of Cancer Research and Cancer Research Technology Limited. Novel chemical compounds developed by the collaboration have been shown to increase the effectiveness of current cancer therapeutics in in-vivo cancer models.

SKIL® (Sareum Kinase Inhibitor Library) is Sareum’s drug discovery technology platform that has so far produced the Company’s Aurora, VEGFR-3, ALK, FLT3 & TYK2 kinase cancer and auto-immune disease research programmes. SKIL can also generate drug research programmes against other kinase targets.

Sareum Holdings plc joined the AIM market of the London Stock Exchange in October 2004, trading under the symbol SAR.  For further information, please visit www.sareum.co.uk